Parasitic worms express host-like glycans to attenuate the immune response of human hosts. The therapeutic potential of this immunomodulatory mechanism in controlling the metabolic dysfunction that is associated with chronic inflammation remains unexplored. We demonstrate here that administration of lacto-N-fucopentaose III (LNFPIII), a Lewis X -containing immunomodulatory glycan found in human milk and on parasitic helminths, improves glucose tolerance and insulin sensitivity in diet-induced obese mice. This effect is mediated partly through increased interleukin-10 (Il-10) production by LNFPIII-activated macrophages and dendritic cells, which reduces white adipose tissue inflammation and sensitizes the insulin response of adipocytes. Concurrently, LNFPIII treatment upregulates nuclear receptor subfamily 1, group H, member 4 (Fxr-a, also known as Nr1h4) to suppress lipogenesis in the liver, conferring protection against hepatosteatosis. At the signaling level, the extracellular signal-regulated kinase (Erk)-activator protein 1 (Ap1) pathway seems to mediate the effects of LNFPIII on both inflammatory and metabolic pathways. Our results suggest that LNFPIII may provide new therapeutic approaches to treat metabolic diseases. npg
The metabolic syndrome is often associated with obesity and is a major medical and economic concern worldwide. Nutrient surplus is one of the main factors that contribute to the obesity pandemic, as well as to increased metabolic burdens on the mitochondria and the endoplasmic reticulum, leading to subcellular organelle dysfunction 1 . Chronic inflammation is often observed in states of obesity and is a common outcome of these metabolic stresses and a key contributor to the pathologies that are associated with metabolic diseases, such as insulin resistance, type 2 diabetes, atherosclerosis and nonalcoholic fatty liver diseases. Although the features of chronic metabolic-related inflammation (or meta-inflammation) differ from those of acute inflammatory responses to exogenous insults, studies have shown that several pathogen-sensing mechanisms of innate immunity are negative regulators of insulin sensitivity 1 . For example, pattern-recognition receptors and downstream effectors (such as Toll-like receptor-4 (Tlr4), IκB kinase β (Ikk-β), Ikk-ε, tumor necrosis factor α (Tnf-α) and double-stranded RNA-dependent protein kinase) have been shown to be activated by high-fat feeding and induce metabolic diseases [2] [3] [4] [5] [6] . In addition, activation of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (Nlrp3) inflammasome, possibly in response to lipid metabolites (for example, fatty acids or ceramides) 7, 8 , results in the cleavage of pro-caspase-1 (pro-Casp-1) and release of mature Il-1β, which causes insulin resistance 7, 8 .
Resident macrophages and lymphocytes in metabolic tissues, such as white adipose tissue (WAT) and liver, are believed to have important roles in meta-inflammation [9] [10] [11] [12] [13] . For example, obesity triggers the appearance of proinflammatory macrophages in the WAT, where they are histologically presented as crown-like structures (CLS) 14, 15 . These so-called 'classically activated' (or M1) macrophages are partly responsible for the low-grade, chronic inflammation that is associated with metabolic dysregulation 1 . In contrast, adipose-resident macrophages from lean individuals have an 'alternatively activated' (or M2) phenotype 16 , which functions to repair damage inflicted by pro-inflammatory M1 signals 17 . Studies have identified several sources of T helper type 2 (T H 2) cytokines (for example, Il-4 and Il-13) within WAT that mediate alternative activation 10, 13, 18 . Depletion of T H 2 cytokine-producing cells or the downstream mediators in macrophages leads to insulin resistance 10, 13, 19 . In contrast, increased T H 2 cytokine production, as in helminth infection, improves glucose homeostasis 18 . Although it remains unclear how T H 2-biased, antiinflammatory immune responses improve metabolic homeostasis, overexpression of the anti-inflammatory cytokine Il-10 has been shown to improve insulin sensitivity 20 .
The ability to drive T H 2-type and anti-inflammatory responses during helminth infection has been associated with decreased damage to host tissues, prolonging host survival 21 . During infection with Schistosoma mansoni, parasite eggs trapped in host tissues, such as the liver, are the main stimuli for T H 2 cytokine production in mice 22 . Injection of a saline-soluble homogenate of eggs (soluble egg antigen, SEA) is sufficient to induce T H 2 biasing of the immune response 23 . Subsequently, it was shown that glycans and glycoproteins found in SEA, such as the Lewis X -containing LNFPIII, GalNAcβ1-4GlcNAc (LacdiNAc), fucosylated LacdiNAc and omega-1 (a T2 RNase), are capable of mediating immunomodulatory activity [24] [25] [26] [27] . Notably, LNFPIII is one of the major sugars found in postpartum human milk and is thought to have a similar protective immunomodulatory effect in the fetus 28, 29 . These observations suggest that during coevolution with human hosts, S. mansoni parasites expressing immunomodulatory glycans were able to escape detection and had a developmental advantage. In fact, macrophages treated with LNFPIII show a T H 2 cytokine-independent, M2-like phenotype characterized by the expression of the M2 markers arginase 1 (Arg1) and chitinase 3-like 3 (Ym1, also known as Chi3l3) 30 . LNFPIII and other helminth-derived glycans induce Il-10 production 31 , upregulate T regulatory cell numbers 32 and inhibit bacterial lipopolysaccharide-induced inflammatory responses 31 .
The mechanisms through which LNFPIII exerts these antiinflammatory activities remain poorly characterized. It has been shown that LNFPIII signals through several C-type lectin receptors 33 and Tlr4 (ref. 34) , which leads to the activation of Erk. Although helminth infections polarize the immune response toward the T H 2 type, studies have shown that it reduces, rather than exacerbates, the incidence of allergic responses, possibly because of the anti-inflammatory activity of Il-10 (ref. 35 ).
Here we further characterize the unique immunomodulatory activity of LNFPIII and determine whether LNFPIII is effective in dampening chronic inflammation and improving metabolic function in a diet-induced model of type 2 diabetes. Our results show that treatment with LNFPIII or SEA reduces inflammation and increases insulin sensitivity in WAT in an Il-10-dependent manner. Further, LNFPIII directly regulates the lipogenic program in hepatocytes and prevents obesity-induced hepatic steatosis through a newly identified link to the nuclear receptor Fxr-α.
RESULTS
LNFPIII treatment improves insulin sensitivity LNFPIII has been shown to induce M2-like macrophage activation independent of T H 2 cytokines 30 . We confirmed that LNFPIII treatment upregulated Arg1, Ym1 and macrophage galactose-type C-type lectin-1 (Mgl1, also known as Cd301) expression, albeit to a lesser extent than Il-4, in macrophages ( Fig. 1a) . In contrast, LNFPIII was more effective than Il-4 in inducing Il10 expression and release into macrophage-conditioned media (Fig. 1a,b and Supplementary  Fig. 1a ). This effect was blunted when we treated macrophages with PD98059 to block the activity of Erk (Fig. 1b) , which has been implicated in mediating LNFPIII signal transduction 31, 34, 36 . We also found that LNFPIII increased Il-10 production in dendritic cells ( Supplementary Fig. 1b ). The ability of LNFPIII to upregulate Il10 expression was independent of signal transducer and activator of transcription 6 (Stat6) and peroxisome proliferator activator receptor δ (Ppar-δ), which are known effectors of T H 2 cytokines ( Supplementary Fig. 1c ). Taken together, LNFPIII induces an antiinflammatory state that increases Il-10 production.
To determine whether the immunomodulatory activity of LNFPIII might be beneficial for treating metabolic diseases, we injected 8-week-old male mice (C57BL/6) with vehicle or LNFPIII (25 µg, twice a week) for 4-6 weeks after the onset of high-fat diet (HFD)induced obesity and metabolic dysfunction. Consistent with the in vitro study, LNFPIII-treated mice had higher circulating concentrations of Il-10 but the same concentrations of Il-4 compared to vehicle-treated mice ( Fig. 1c) . When subjected to glucose tolerance tests (GTTs), LNFPIII-treated mice showed significantly higher glucose-handling capability compared to the vehicle-treated control group ( Fig. 1d ; area under the curve (AUC), vehicle = 36,727.5 ± 1,769.13 (mean ± s.e.m.); LNFPIII = 29,244± 1,119.7, P = 0.0159). LNFPIII treatment also led to higher insulin sensitivity compared to vehicle treatment, as shown by reductions in fasting serum insulin concentrations (vehicle, 1.54 ± 0.07 ng ml −1 ; LNFPIII: 1.29 ± 0.06 ng ml −1 , P < 0.05), and improvements in both the results of insulin tolerance tests (ITTs) (AUC, vehicle = 123.58 ± 4.79; LNFPIII = 98.23 ± 3.30, npg P = 0.0357) and the homeostasis model of assessment-insulin resistance (HOMA-IR) ( Fig. 1e) . We found enhanced insulin signaling, determined by insulin-stimulated Ser473 Akt phosphorylation, in WAT but not in liver or muscle of mice treated with LNFPIII ( Fig. 1f,g and data not shown). We conducted parallel metabolic studies with SEA treatment, which led to higher circulating Il-10 and Il-4 concentrations than vehicle treatment ( Supplementary Fig. 1d ). HFD-fed mice treated with SEA also showed an improved insulin response compared to vehicle-treated mice, as determined by GTTs, ITTs, fasting insulin concentrations and HOMA-IR ( Supplementary  Fig. 1e-g) . Treatment with LNFPIII or SEA did not affect body weight, food intake or circulating concentrations of lipids or adiponectin ( Supplementary Table 1 ). These studies demonstrate the potential of using glycans derived from S. mansoni egg extract, including LNFPIII, to improve glucose homeostasis and insulin sensitivity.
LNFPIII enhances WAT insulin signaling through Il-10
The interaction between resident macrophages and adipocytes has an important role in adipose tissue metabolic homeostasis 10 . WAT histological analyses demonstrated that mice given LNFPIII had lower numbers of CLSs and lower expression of F4/80 (a macrophage marker also known as Emr1; Fig. 2a,b ) compared to vehicle-treated mice. In addition, Il10 and M2 genes (Arg1 and Mgl1) were upregulated and Tnfa and genes encoding the inflammasome (Casp1, Nlrp3, Il18 and Il1b) were downregulated by LNFPIII treatment (Fig. 2b) .
Consistent with the higher insulin sensitivity, the expression of insulin receptor β (InsRb), insulin receptor substrate 2 (Irs2), CCAAT/enhancer binding protein α (C/ebpa), glucose transporter 4 (Glut4, also known as Slc2a4) and lipogenic genes was higher in WAT from LNFPIIItreated mice than from vehicle-treated control mice ( Fig. 2c) . C/ebp-α and Irs2 protein abundances were also higher in these mice than in controls ( Fig. 2d) . We obtained similar results in SEA-treated cohorts of mice (Supplementary Fig. 2) . Of note, SEA induced Arg1 expression in WAT to a greater extent than did LNFPIII, reflecting the fact that SEA treatment increased serum Il-4 concentrations ( Supplementary  Fig. 1d) . These data support the notion that LNFPIII modulates WAT-resident macrophage inflammation and improves adipose tissue metabolic homeostasis. Both in vitro and in vivo studies demonstrated that LNFPIII induced an anti-inflammatory phenotype characterized by elevated Il-10 concentrations, a cytokine that has been shown to improve metabolic homeostasis 20 . To address whether the insulin-sensitizing effect in WAT of LNFPIII injection is a direct action of the glycan or is mediated by Il-10, we cultured 3T3-L1 adipocytes with or without LNFPIII or recombinant Il-10 (rIl-10). We found that rIl-10, but not LNFPIII, improved insulin responsiveness, as determined by insulinstimulated Akt phosphorylation, glucose uptake and lipogenesis ( Fig. 3a) . Conditioned medium from LNFPIII-primed wild type (WT) macrophages, which contained higher Il-10 concentrations than vehicle-primed conditioned medium (Fig. 1b) , was able to reproduce the insulin-sensitizing activity in 3T3-L1 adipocytes, an effect that was abrogated in conditioned medium from LNFPIII-primed Il10 −/− macrophages (Fig. 3b) . Furthermore, conditioned medium derived from LNFPIII-primed WT, but not Il10 −/− , macrophages induced the expression of InsR, Irs2 and C/ebpa and suppressed the expression of Il1b and Tnfa in 3T3-L1 adipocytes (Fig. 3c) . Reconstitution of rIl-10 in conditioned medium from Il10 −/− macrophages restored its ability to improve insulin-stimulated glucose uptake and modulate metabolic and inflammatory gene expression (Fig. 3b,c) . In vivo, LNFPIII was unable to improve insulin tolerance ( Fig. 3d and  Supplementary Table 1) , enhance insulin-stimulated glucose uptake (Fig. 3e) or inhibit WAT inflammation (Supplementary Fig. 3a,b) in Il10 −/− mice. In addition, Il10 −/− mice were more insulin resistant than WT control mice (Supplementary Fig. 3c) . Reciprocally, rIl-10 injections (1 µg every other day for three total doses) improved glucose tolerance and insulin sensitivity and recapitulated the WAT phenotype in LNFPIII-treated mice (Supplementary Fig. 3d-h and Supplementary Table 1 ). Taken together, the results suggest that Il-10 is required for LNFPIII-mediated improvement in WAT insulin signaling and systemic glucose homeostasis.
LNFPIII protects against diet-induced hepatic steatosis
In addition to improving WAT function, histological and triglyceride content analyses showed a strong protective effect of treatment with LNFPIII against HFD-induced hepatic lipid accumulation compared to treatment with vehicle ( Fig. 4a) . Furthermore, overall liver function, determined by circulating concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), was substantially better in LNFPIII-treated mice than in vehicletreated control mice (Fig. 4b) . In line with lower hepatic steatosis, the expression of lipogenic genes, including fatty acid synthase (Fas), acetyl-CoA carboxylases 1 and 2 (Acc1 and Acc2, also known as Acaca and Acacb, respectively), stearoyl-CoA desaturase 1 (Scd1) and sterol regulatory element-binding protein 1c (Srebp1c, also known as Srebf1), were lower in LNFPIII-treated livers than in vehicle-treated livers (Fig. 4c) .
Srebp-1c is a master lipogenic transcription factor whose expression and transcriptional activity are controlled by a network of nuclear receptor signaling pathways, notably, the positive regulator nuclear receptor subfamily 1, group H, member 3 (Lxr-α, also known as Nr1h3) 37 and the negative regulators Fxr-α (also known as Nr1h4) and its target nuclear receptor subfamily 0, group B, member 2 (Shp, also known as Nr0b2) 38 . The Fxr-α gene consists of two major 5′ regulatory regions, with the upstream and downstream promoters driving the expression of two isoforms of the gene, referred to here as Fxr-α1 and Fxr-α2, and Fxr-α3 and Fxrα4, respectively 39 . The only difference between Fxr-α1 and Fxr-α2 (or Fxr-α3 and Fxr-α4) is a four-amino-acid insertion in Fxr-α1 (or Fxr-α3). We found that expression of the Fxr-α3/α4 isoforms, as well as several known Fxr target genes 39 , including Shp, organic anion-transporting polypeptides (Oatp, also known as Slco1a1), phospholipid transfer protein (Pltp) and bile salt efflux pump (Bsep, also known as Abcb11), were upregulated in the livers of LNFPIIItreated mice compared to vehicle-treated control mice (Fig. 4c) . The expression of the Lxr-α gene was the same in LNFPIII-treated and vehicle-treated mice. We obtained similar effects with SEA treatment, except that SEA upregulated both Fxr-α1/α2 and Fxr-α3/α4 (Supplementary Fig. 4a-d) . Treatment with LNFPIII or SEA did not alter metabolic gene expression in muscle ( Supplementary Fig. 4e and data not shown). These results indicate that LNFPIII prevents To assess the role of LNFPIII or LNFPIII-primed macrophages in hepatic lipid homeostasis, we conducted lipogenic assays in isolated primary hepatocytes. LNFPIII, but not conditioned medium from LNFPIII-treated macrophages, suppressed lipogenesis and caused higher fatty acid β-oxidation compared to vehicle treatment (Fig. 5a) . LNFPIII also induced expression of Fxr-α3/α4 and Shp and suppressed the expression of Srebp1c and Acc1 (Fig. 5b) . As LNFPIII did not affect the expression of β-oxidation genes (Figs. 4c and 5b) , the increased fat burning resulting from LNFPIII treatment was probably secondary to the decreased fatty acid synthesis. These results suggest that, unlike in WAT, the effect of LNFPIII in the liver was not mediated by Il-10. Consistent with this notion, rIl-10 treatment did not affect hepatic de novo lipogenesis in vitro or in vivo ( Supplementary  Fig. 5a-c) , and the protective effect of LNFPIII was preserved in Il10 −/− liver (Supplementary Fig. 5d,e ).
LNFPIII suppresses hepatic de novo lipogenesis through Fxr
The upregulation of the Fxr-α-dependent transcription program by LNFPIII suggested that LNFPIII may induce Fxr-α to inhibit fat synthesis. In fact, in hepatocytes with ablation of the Fxr-α gene npg or inhibition of Erk by PD98059, LNFPIII was unable to inhibit de novo lipogenesis and increase fat oxidation (Fig. 5c) . Furthermore, the ability of LNFPIII to reduce hepatic triglyceride accumulation, improve liver function and suppress lipogenic gene expression was lost in Nr1h4 −/− mice (Fig. 5d,e and Supplementary Fig. 5f) , whereas the insulin-sensitizing activity of LNFPIII was unaffected (Supplementary Fig. 5g-i and Supplementary Table 1 ). Together, these results suggest that LNFPIII inhibits hepatic lipogenesis in a Fxr-α-dependent manner. We next sought to determine whether Fxr-α is a molecular target of LNFPIII. As mentioned above, both the human and mouse FXR-α genes contain two major promoters (Fig. 6a) . The 5′ proximal regulatory sequences are highly conserved between the mouse, rat and human FXR-α genes (Supplementary Fig. 6a) . We examined the activities of reporters driven by regulatory regions of promoter 1 or promoter 2 in the FXR-α gene in HepG2 cells (human hepatoma cells). In accordance with the regulation of the Fxr-α gene in the liver or isolated hepatocytes, LNFPIII activated human promoter 2, whereas SEA induced the activity of both promoters (Fig. 6a) . In vivo, Fxr-α protein abundance was higher in liver lysates from LNFPIIItreated compared to vehicle-treated mice (Fig. 6a) . Through serial deletion of promoter 2, we defined a minimal LNFPIII-responsive region (approximately 130 bp upstream of the transcriptional start site) that contained consensus binding sites for C/EBP and AP1 (Supplementary Fig. 6a ). Site-directed mutagenesis experiments further identified two overlapping AP1 sites (located between −57 bp and −47 bp) that were required for the induction of promoter 2 by LNFPIII ( Fig. 6b and Supplementary Fig. 6b) . Similarly, inhibition of Erk activation, which is upstream of AP1, by PD98059 abolished the LNFPIII-induced activity of promoter 2. In concert, LNFPIII treatment increased the amounts of phosphorylated Erk and total Erk in the liver (Fig. 6c) and hepatocytes (Fig. 6d) . We obtained similar results in SEA-treated liver cells ( Supplementary Fig. 6c,d) .
Collectively, these findings suggest that LNFPIII regulates hepatic lipogenesis through the Erk-Ap1-Fxr-α axis.
DISCUSSION
In this study, we demonstrate that LNPFIII (and SEA) alleviates the pathologies that are associated with HFD-induced obesity. LNFPIII treatment shifts the immune profile to an anti-inflammatory state and decreases macrophage infiltration in metabolic tissues of mice that have already become obese. This effect is, in part, driven by Il-10, which inhibits inflammation and enhances the insulin response in WAT. In the liver, LNFPIII upregulates the bile acid sensing nuclear receptor Fxr-α and its downstream transcriptional targets. Activated Fxr-α signaling suppresses lipogenesis and protects against hepatic steatosis. Taken together, our results demonstrate a therapeutic potential for LNFPIII in treating components of metabolic syndrome through its ability to directly modulate both immune and metabolic pathways.
The hygiene hypothesis attributes the increased incidence of autoimmune diseases and allergic responses in developed countries to reduced human contact with pathogens 40 . A special emphasis has been on the interaction between parasitic worms and humans 40, 41 ; in addition to the T H 2-biasing immune phenotype, helminth infections induce the proliferation of regulatory T cells and production of the anti-inflammatory cytokine Il-10 (ref. 42) . Our data show that LNFPIII treatment is sufficient to increase Il-10 production in macrophages and dendritic cells. Regulatory T cells are probably another major source of Il-10 (ref. 42 ). These cells are enriched in fat tissues from lean individuals and have a role in maintaining WAT function 9 . Anti-inflammatory pathways are thought to improve metabolic homeostasis primarily through attenuating the action of proinflammatory signaling. Overexpression of Il-10 in the muscle was previously shown to improve systemic insulin resistance through suppression of inflammation 20 . We found that conditioned medium from LNFPIII-treated WT macrophages directly enhances insulin responses in adipocytes by upregulation of InsR and Irs2 and increases insulin-mediated glucose uptake and lipogenesis in an Il-10-dependent manner. Acute rIl-10 injection in HFD-fed mice also improved glucose homeostasis but does not affect WAT macrophage infiltration (data not shown), suggesting that the insulin-sensitizing effect of Il-10 can be separated from its anti-inflammatory activity.
Several studies have identified IL10 polymorphisms that are associated with insulin resistance and type 2 diabetes in humans 43, 44 . Of note, a previous study has demonstrated that deficiency in hematopoietic cell-derived Il-10 in mice through transplantation of Il10 −/− bone marrow does not affect HFD-induced tissue inflammation and insulin resistance 45 . However, Il10 mRNA and protein abundances were several fold higher in WAT and liver in these mice than in mice that received WT bone marrow. It is unclear whether the compensatory increase in Il-10 production is from nonhematopoietic cells or residual WT bone marrow-derived cells. The result seems to suggest that increased Il-10 concentrations within metabolic tissues are sufficient to maintain metabolic homeostasis.
Although adipose tissue is known to produce adipokines, such as leptin, adiponectin and resistin, that modulate systemic glucose and lipid metabolism, this tissue, unlike the muscle, is not a major tissue for glucose uptake under physiological conditions. LNFPIII treatment did not affect the expression of these adipokines in WAT ( Supplementary  Table 1 and data not shown). How does increased insulin sensitivity in WAT after LNFPIII treatment lead to improvement in systemic glucose homeostasis? It has been shown that GTT and ITT values in musclespecific insulin receptor knockout (MIRKO) mice are indistinguishable from those in control mice, even though insulin-stimulated glucose uptake is substantially lower in the muscle of the knockout mice 46 . Subsequent studies attribute the normoglycemic phenotype of MIRKO mice to a threefold higher glucose deposition to the WAT compared to control mice 47 , suggesting that, at least in mice, increased glucose uptake by adipocytes is able to sustain glucose homeostasis. Consistent with this notion, overexpression of the glucose transporter Glut4 in adipose tissues improves glucose tolerance 48 . Recently, increased glucose flux in adipocytes has been shown to upregulate fatty acid synthesis through a new isoform of carbohydrate-responsive element-binding protein (Chrebp-β, also known as Mlxipl) 49 . In addition, the expression of adipose MLXIPL and lipogenic genes positively correlates with insulin sensitivity in humans 49 . Our data demonstrate that LNFPIII treatment increases WAT glucose uptake and lipogenic gene expression, and Mlxipl was also induced (data not shown).
Although the mechanism through which fat synthesis in adipose tissues contributes to whole-body homeostasis is not completely understood, a lipogenic product of adipocytes has been linked to improved systemic metabolism 50 . The beneficial effect of LNFPIII could also be mediated by central regulation, in which reduced inflammation may lead to the improved central insulin sensitivity that is known to regulate hepatic glucose production 51 . However, LNFPIII does not seem to affect gluconeogenesis, as determined by pyruvate tolerance tests and the expression of gluconeogenic genes in the liver (data not shown).
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Egg deposition in the liver is crucial for the induction of a systemic T H 2 response 22 . It is therefore not surprising that the liver is also a target of LNFPIII. At first glance, it seems unexpected that LNFPIII directly controls Fxr-α signaling to regulate hepatic lipid metabolism. Fxr-α senses endogenous bile acids and controls bile acid homeostasis by inhibiting production while increasing the recycling of bile acids in the enterohepatic system 52 . Fxr-α activation also suppresses lipogenesis through Shp-mediated inhibition of Srebp-1c in the liver 38 . Interestingly, S. mansoni is incapable of de novo synthesis of fatty acids and sterols but is able to synthesize complex lipids from precursors acquired from the host 53 . In addition, it has been shown that bile acids increase the number of deposited parasite eggs 54 . Therefore, the induction of Fxr-α by LNFPIII could be the host's response to limit the fatty and bile acids available to the worm. In contrast, bile acids facilitate lipid absorption in the intestine. Increased bile flow by Fxr-α may help schistosomes extract lipids from the digestive system of the host. Additionally, the induction of Fxr-α could serve as an anti-inflammatory mechanism in the liver, as Fxr-α is known to trans repress Nf-κb activity 55 .
The signal transduction pathway of LNFPIII has not been fully characterized. In dendritic cells, LNFPIII is recognized by multiple C-type lectin receptors, including DC-SIGN (also known as Cd209), Mgl1 and mannose receptor. In addition, Erk is proposed to be a downstream effector of LNFPIII 31, 56 . Erk-Ap1 has been shown to regulate Il10 expression 36 . Indeed, the ability of LNFPIII to induce Il-10 production in the macrophage was blocked by Erk inhibition. We find that primary hepatocytes also express C-type lectin receptors, including DC-SIGN (data not shown), and LNFPIII is able to activate Erk in the liver, which mediates transcriptional regulation of the Fxr-α gene and the subsequent suppression of lipogenesis. The gene products of the two promoters (Fxr-α1 and Fxr-α2 compared to Fxr-α3 and Fxr-α4) differ by several amino acids located at the N terminus. Functional differences between the isoforms have not been reported 39 . Our data suggests that the induction of Fxr-α3 and Fxr-α4 by LNFPIII is sufficient to suppress lipogenesis. Whereas LNFPIII only activates the downstream promoter, SEA induces the activities of both promoters. This is not unexpected, as SEA is known to contain multiple bioactive glycans that could signal through different pathways 56 . Together, our data show that helminths may utilize the Erk-Ap1 signaling pathway to modulate host metabolism and immune responses ( Fig. 6e) . Our study suggests that the M2-like, anti-inflammatory activity of LNFPIII, which is probably a product of the survival strategy of helminths, may be used to treat metabolic disorders such as insulin resistance and nonalcoholic fatty liver diseases.
METHODS
Methods and any associated references are available in the online version of the paper.
